A New Frontier In Medicine
We are building a portfolio of novel differentiated GPCR biotherapeutics utilizing our unique discovery platform to create new medicines
Program
Indication / Therapeutic Area
Status
Discovery
Hit-to-Lead
Lead Optimization
IND-Enabling Studies
GPCR 001
Idiopathic pulmonary fibrosis (IPF)
Hit-to-Lead
GPCR 002
Autosomal dominant polycystic kidney disease (ADPKD)
Hit-to-Lead
GPCR 003/004 (multispecific)
Migraine
Hit-to-Lead
GPCR 005
Dermatology
Discovery
GPCR 006
Graves’ disease
Discovery
